Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
The last few years have seen an increased interest in immunotherapy in the treatment of malignant disease. In particular, there has been significant enthusiasm for oncolytic virotherapy, with a large amount of pre-clinical data showing promise in animal models in a wide range of tumour types. How do...
Main Authors: | Samantha Turnbull, Emma J. West, Karen J. Scott, Elizabeth Appleton, Alan Melcher, Christy Ralph |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-12-01
|
Series: | Viruses |
Subjects: | |
Online Access: | http://www.mdpi.com/1999-4915/7/12/2938 |
Similar Items
-
Oncolytic Virotherapy for Cancer: Clinical Experience
by: Shyambabu Chaurasiya, et al.
Published: (2021-04-01) -
Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection
by: Tarryn Bourhill, et al.
Published: (2018-08-01) -
Modifying oncolytic virotherapy to overcome the barrier of the hypoxic tumor microenvironment. Where do we stand?
by: Sara Shayan, et al.
Published: (2022-11-01) -
Twenty Years after Bovine Vaccinia in Brazil: Where We Are and Where Are We Going?
by: Iago José da Silva Domingos, et al.
Published: (2021-03-01) -
Past, Present and Future of Oncolytic Reovirus
by: Louise Müller, et al.
Published: (2020-10-01)